Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer

BACKGROUND: Olaparib is an oral inhibitor of polyadenosine 5’-diphosphoribose polymerization (PARP) that has previously shown signs of activity in patients with BRCA mutations and pancreatic ductal adenocarcinoma (PDAC). PATIENTS AND METHODS: In this phase 1 dose-escalation trial in patients with un...

Descripción completa

Detalles Bibliográficos
Autores principales: Yarchoan, Mark, Myzak, Melinda C., Johnson, Burles A., De Jesus-Acosta, Ana, Le, Dung T., Jaffee, Elizabeth M., Azad, Nilofer S., Donehower, Ross C., Zheng, Lei, Oberstein, Paul E., Fine, Robert L., Laheru, Daniel A., Goggins, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546463/
https://www.ncbi.nlm.nih.gov/pubmed/28454122
http://dx.doi.org/10.18632/oncotarget.17237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546463/
https://www.ncbi.nlm.nih.gov/pubmed/28454122
http://dx.doi.org/10.18632/oncotarget.17237

Ejemplares similares